Mitsui took part in oncology therapy developer Ensem Therapeutics' $67m series A round while Bioventus is paying up to $450m to buy the rest of portfolio company CartiHeal.
Funding
US-based cancer drug developer Ensem Therapeutics completed a $67m series A round yesterday featuring diversified conglomerate Mitsui, which took part through its Mitsui & Co Global Investment unit. Venture capital firm GGV Capital led the round, which included Pavilion Capital, Cenova Capital and CBC Group, the healthcare investment firm that incubated the startup.
Germany-based digital preventive healthcare provider Avi Medical received €50m ($54.5m) in funding yesterday from investors including consumer product distributor Vorwerk’s corporate VC unit, Vorwerk Ventures. The…
